Clinical Trials
8 trialsNCT04802161 2025-12-19
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02029950 2020-10-14
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT00669578 2019-12-30
CC-4047 in Treating Patients With Myelofibrosis
Mayo Clinic
Phase 1/2 Completed
NCT00463385 2019-11-20
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Celgene
Phase 2 Completed
NCT01178281 2019-07-17
RESUME
Celgene
Phase 3 Completed
NCT00946270 2019-06-10
Pomalidomide for Myelofibrosis Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT00949364 2017-09-25
Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
University of Ulm
Phase 2 Completed